CSF phosphorylated tau protein and mild cognitive impairment: A prospective study

Hiroyuki Arai, Koichi Ishiguro, Hideto Ohno, Michiko Moriyama, Nobuo Itoh, Nobuyuki Okamura, Toshifumi Matsui, Yu ichi Morikawa, Etsuo Horikawa, Hideki Kohno, Hidetada Sasaki, Kazutomo Imahori

Research output: Contribution to journalArticlepeer-review

118 Citations (Scopus)


Cerebrospinal fluid (CSF) tau protein phosphorylated at both Thr231 and Ser235 sites (CSF/phospho-tau231-235) and total tau (CSF/total-tau) were quantified by sandwich ELISA in 20 patients with mild cognitive impairment (MCI) who eventually developed AD on follow-up as well as seven memory complainers with no objective memory loss. 13/20 (65%) of the MCI patients had high CSF/total-tau and detectable levels of CSF/phospho-tau231-235, whereas these markers were low and under a detectable level in all of the memory complainers. Although either a total-tau, phospho-tau measurement or a combination of these can help in predicting if MCI will develop AD, our results suggest that the pathogenic steps of AD may be at the stage that finally leads to an accumulation of abnormally phosphorylated tau and neuron death, at least in some brain areas, when MCI patients present with the earliest detectable clinical symptoms of dementia. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)201-203
Number of pages3
JournalExperimental Neurology
Issue number1
Publication statusPublished - 2000
Externally publishedYes


  • Alzheimer's disease
  • Cerebrospinal fluid
  • Enzyme immunoassay
  • Mild cognitive impairment
  • Phosphorylated tau
  • Prospective study

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience


Dive into the research topics of 'CSF phosphorylated tau protein and mild cognitive impairment: A prospective study'. Together they form a unique fingerprint.

Cite this